false
Catalog
Navigating Clinical Trials: Essential Knowledge fo ...
Health Equity in Clinical Trials
Health Equity in Clinical Trials
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
Dr. Susan Taylor discusses health equity in dermatologic clinical trials, highlighting significant gaps in inclusivity. She explains that underrepresentation of diverse population groups in trials can lead to incomplete understanding of drug safety and efficacy, limiting the generalizability of trial findings. Studies demonstrate that non-white and Hispanic participants are underrepresented, particularly in Phase III trials for conditions like acne, atopic dermatitis, and psoriasis. Cultural considerations, such as religious practices, are crucial in recruitment strategies. Barriers to participation include mistrust, lack of information, and financial burdens. Dr. Taylor emphasizes solutions, such as involving community leaders and providing compensation. She also highlights the importance of training dermatologists in conducting inclusive trials. This initiative aims to address disparities in clinical trial participation, ensuring equitable healthcare outcomes across diverse populations.
Asset Subtitle
by Susan Taylor, MD, FAAD
Keywords
health equity
dermatologic trials
underrepresentation
cultural considerations
inclusive recruitment
equitable healthcare
Legal notice
Copyright © 2025 American Academy of Dermatology. All rights reserved.
Reproduction or republication strictly prohibited without prior written permission.
×
Please select your language
1
English